References
- Edelman R. Prevention and treatment of infectious diarrhoea. Speculations on the next 10 years. Am J Med 1985; 78: 99–106
- Schiller L R, Santa Ana C A, Morawski S G, Fordtran J S. Mechanism of the antidiarrhoeal effect of loperamide. Gastroenterology 1984; 86: 1475–80
- Marcais-Collado H, Uchida G, Costentin J, Schwartz J C, Lecomte J M. Naloxone-reversible antidiarrhoeal effects of enke-phalinase inhibitors. Eur J Pharmacol 1987; 144: 125–32
- Lecomte J M, Costentin J, Vlaiculescu A. Pharmacological properties of acetorphan a parenterally active ‘enkephalinase’ inhibitor. J Pharmacol Exp Ther 1986; 237: 937–44
- Primi M P, Bueno L, Ph Baumer, Berard H, Schwartz J C, Lecomte J M. Action antisécrétoire intestinale d'un inhibiteur de l'enképhalinase, l'acétorphan: démonstration in vivo chez le chien. Gastroenterol Clin Biol 1991; 15: A73
- Bergmann J F, Chaussade S, Couturier D, Ph Baumer, Schwartz J C, Lecomte J M. Effects of acetorphan, an antidiarrhoeal enkephalinase inhibitor, on orocaecal and colonic transit times in healthy volunteers. Aliment Pharmacol Ther 1992; 6: 305–13
- Ph Baumer, Danquechin Dorval E. Effects of acetorphan, an enkephalinase inhibitor, on experimental and acute diarrhoea. Gut 1992; 33: 753–8
- Gorbach S L. Infectious diarrhoea. Gastrointestinal diseases. 4th ed., MH Sleisenger, JS Fordtran. WB Saunder, Philadelphia 1989; 1191–232
- Ruppin H. Review: loperamide—a potent antidiarrhoeal drug with actions along the alimentary tract. Aliment Pharmacol Ther 1987; 1: 179–90
- Schiller L R, Davis G R, Santa Ana C A, Morawski S G, Fordtran J S. Studies on the mechanism of the antidiarrhoeal effect of codeine. J Clin Invest 1982; 70: 999–1008
- Garrett J M, Sauer W G, Moertel C G. Colonic motility in ulcerative colitis after opiate administration. Gastroenterology 1967; 53: 93–100
- Du Pont H L, Hornick R B. Adverse effect of lomotil therapy in shigellosis. JAMA 1973; 226: 1525–8
- Brown J W. Toxic megacolon associated with loperamide therapy. JAMA 1979; 241: 501–2
- Olm M, Gonzalez F J, Garcia-Valdecasas J C, Fuster J, Bertran A, Milla J. Necrotising colitis with perforation in diarrhoeic patients treated with loperamide. Eur J Clin Pharmacol 1991; 40: 415–6
- Schuermans V, Lommel R V, Dom J, Brugmans J. Loperamide (R18553), a novel type of diarrhoeal agent. Placebo-controlled comparison of the constipation activity and safety of loperamide, diphenoxylate and codeine in normal volunteers. Arznei-mittelforsch (Drug Res) 1974; 24: 1653–7
- Chipkin R E, Berger J G, Billard W, Iorio L C, Chapman R, Barnett A. Pharmacology of SCH 34826, an orally active enkephalinase inhibitor analgesic. J Pharmacol Exp Ther 1988; 245: 829–37
- Shook J E, Lemcke P K, Gehrig C A, Hruby V J, Burk T. Antidiarrhoeal properties of supraspinal mu and delta and peripheral mu delta and kappa opioid receptors: inhibition of diarrhoea without constipation. J Pharmacol Exp Ther 1989; 249: 83–90
- Knisely J S, Beardsley P M, Aceto M D, Balster R L, Harris L S. Assessment of the abuse potential of acetorphan an enkephalinase inhibitor. Drug Alcohol Depend 1989; 23: 143–51
- Loperamide. The rational use of drugs in the management of acute diarrhoea in children. World Health Organisation, Geneva 1990; 17–22